IMMP: מזומנים בחישוב למניה אחת Immutep Corp

Immutep Limited develops advanced immunotherapy methods across centers in Europe and Australia. This chart from the GURU.Markets system displays liquid assets per share, where the value of 6.46 reflects the current solvency status. Immutep Limited aims for global expansion of its oncology pipeline through strategic alliances. Currently, the biotech sector is focused on the publication of LAG-3 protein trial results for the treatment of lung and breast cancer.
פילוחים אנליטיים של חברת Immutep Limited

This indicator reflects the amount of available cash per ordinary share, allowing for an assessment of the company's internal resources to cover obligations without resorting to external borrowing. By analyzing the level of liquid assets per share, an investor can gauge the financial autonomy of Immutep Limited (IMMP), which is critical for sustaining an organic R&D model and conducting large-scale clinical trials in partnership with pharmaceutical behemoths.